Abstract Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …

Treatment of chronic myeloid leukemia (CML) with interferon-alpha (IFN-α) was introduced
in the early 1980s. Several clinical trials showed a survival advantage for patients treated …

Interferon-alpha (IFNα) was once the standard of frontline treatment for chronic myeloid
leukemia (CML). Its pleiotropic mechanism of action in CML includes immune activation and …

Biological agents have long been used in the treatment of cancer, and interferon-alpha was
the first human cytokine to be widely studied in this setting. Chronic myeloid leukemia (CML) …

Before the introduction of imatinib, interferon α-based regimens were the gold standard for
treatment of early chronic phase chronic myeloid leukemia patients. The combination of IFN …

Purpose Imatinib induces sustained remissions in patients with chronic myelogenous
leukemia (CML), but fails to eradicate CML stem cells. This is of major concern regarding the …

Patients with chronic myeloid leukemia now have several potential treatment options from
which to choose. Imatinib mesylate currently provides excellent hematologic and cytogenetic …

Background Imatinib (400 mg daily) is considered the best initial therapy for patients with
newly diagnosed chronic myeloid leukemia (CML) in the chronic phase. However, only a …

A minority of chronic myeloid leukemia (CML) patients is capable of successfully
discontinuing imatinib. Treatment modalities to increase this proportion are currently …

Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for
chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML …